Symic Bio has struck a long-term lease for 24,378 square feet of office/biotech lab space that will reposition and quickly expand the company from San Francisco across the bay into Emeryville, CA. Currently operating in just a few thousand square feet of incubator space in San Francisco’s Dogpatch neighborhood, the fast-growing clinical-stage biotherapeutics company will be moving into a multi-story Class A building known as EmeryStation North located at 5858 Horton Street. Owned by Wareham Development, the building is part of a larger mixed-use, transit-oriented campus that serves home to other life science tenants such as Nanomix, Inc., Novartis, and NovaBay Pharmaceutical. Symic is scheduled to move to its new Emeryville space later this year. Chris Johnke, Cameron Love, Cale Miller, Erich Sollman, Gabe Burke, Dan Latini, and Steven Gargiulo with Cushman & Wakefield’s San Francisco office represented the tenant in the transaction.
About Symic Bio
Symic Bio is developing multiple compounds that target and affect the extracellular matrix (ECM), the non‐cellular component of tissues that is critical for healthy tissue function. Symic Bio plans to advance its compounds in a variety of therapeutic areas with unmet clinical needs.